Article

Measurement of Serum Acetaminophen–Protein Adducts in Patients With Acute Liver Failure

University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Gastroenterology (Impact Factor: 16.72). 04/2006; 130(3):687-94. DOI: 10.1053/j.gastro.2006.01.033
Source: PubMed

ABSTRACT

Acetaminophen toxicity is the most common cause of acute liver failure (ALF) in the United States and Great Britain, but may be underrecognized in certain settings. Acetaminophen-protein adducts are specific biomarkers of drug-related toxicity in animal models and can be measured in tissue or blood samples. Measurement of serum adducts might improve diagnostic accuracy in acute liver failure (ALF) patients.
We measured serum acetaminophen-protein adducts using high-pressure liquid chromatography with electrochemical detection in coded sera of 66 patients with ALF collected prospectively at 24 US tertiary referral centers. Samples were included from 20 patients with well-characterized acetaminophen-related acute liver failure, 10 patients with ALF owing to other well-defined causes, 36 patients with ALF of indeterminate etiology, and 15 additional patients without ALF but with known acetaminophen overdose and minimal or no biochemical liver injury.
Acetaminophen-protein adducts were detected in serum in 100% of known acetaminophen ALF patients and in none of the ALF patients with other defined causes, yielding a sensitivity and specificity of 100%. In daily serial samples, serum adducts decreased in parallel with aminotransferase levels. Seven of 36 (19%) indeterminate cases demonstrated adducts in serum suggesting that acetaminophen toxicity caused or contributed to ALF in these patients. Low adduct levels were present in 2 of 15 patients with acetaminophen overdose without significant liver injury.
Measurement of serum acetaminophen-protein adducts reliably identified acetaminophen toxicity, and may be a useful diagnostic test for cases lacking historical data or other clinical information.

Download full-text

Full-text

Available from: Anne M Larson
  • Source
    • "In patients with ALF of unknown etiology (i.e., lack of a definitive diagnosis despite laboratory testing), up to 18 % of samples were shown to have toxic levels of adducts (Davern et al. 2006; Khandelwal et al. 2011). Moreover, the biochemical profiles (hyper-acute elevation of ALT, "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acetaminophen (APAP) is a commonly used analgesic drug that can cause liver injury, liver necrosis and liver failure. APAP-induced liver injury is associated with glutathione depletion, the formation of APAP protein adducts, the generation of reactive oxygen and nitrogen species and mitochondrial injury. The systems biology omics technologies (transcriptomics, proteomics and metabolomics) have been used to discover potential translational biomarkers of liver injury. The following review provides a summary of the systems biology discovery process, analytical validation of biomarkers and translation of omics biomarkers from the nonclinical to clinical setting in APAP-induced liver injury.
    Full-text · Article · May 2015 · Archives of Toxicology
  • Source
    • "The role of ASK1 and JNK activation during APAP overdose in humans remains unclear. More recent translational studies support the hypothesis that protein adduct formation and mitochondrial dysfunction are important for the human pathophysiology (Davern et al., 2006; McGill et al., 2012, 2014). Although APAP causes extensive JNK activation and mitochondrial p-JNK translocation in primary human hepatocytes , the protection by inhibition of JNK was modest (Xie et al., 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic activation and oxidant stress are key events in the pathophysiology of acetaminophen (APAP) hepatotoxicity. The initial mitochondrial oxidative stress triggered by protein adduct formation is amplified by c-jun-N-terminal kinase (JNK), resulting in mitochondrial dysfunction and ultimately cell necrosis. Apoptosis signal-regulating kinase 1 (ASK1) is considered the link between oxidant stress and JNK activation. The objective of the current study was to assess the efficacy and mechanism of action of the small-molecule ASK1 inhibitor GS-459679 in a murine model of APAP hepatotoxicity. APAP (300 mg/kg) caused extensive glutathione depletion, JNK activation and translocation to the mitochondria, oxidant stress and liver injury as indicated by plasma ALT activities and area of necrosis over a 24h observation period. Pretreatment with 30 mg/kg of GS-459679 almost completely prevented JNK activation, oxidant stress and injury without affected the metabolic activation of APAP. To evaluate the therapeutic potential of GS-459679, mice were treated with APAP and then with the inhibitor. Given 1.5h after APAP, GS-459679 was still protective, which was paralleled by reduced JNK activation and p-JNK translocation to mitochondria. However, GS-459679 treatment was not more effective than N-acetylcysteine, and the combination of GS-459679 and N-acetylcysteine exhibited similar efficacy as N-acetylcysteine monotherapy, suggesting that GS-459769 and N-acetylcysteine affect the same pathway. Importantly, inhibition of ASK1 did not impair liver regeneration as indicated by PCNA staining. In conclusion, the ASK1 inhibitor GS-459679 protected against APAP toxicity by attenuating JNK activation and oxidant stress in mice and may have therapeutic potential for APAP overdose patients. Copyright © 2015. Published by Elsevier Inc.
    Full-text · Article · Mar 2015 · Toxicology and Applied Pharmacology
  • Source
    • "APAP-protein adducts could accumulate over time since they are more persistent than APAP metabolites. APAP-protein adduct half-life was evaluated at 1–2 days in human plasma after acute overdoses of APAP [22] [23] but is still unknown in liver. To our knowledge, APAP-protein adducts and other protein modifications have never been deeply investigated in the liver after chronic treatments with non-toxic doses of APAP. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver protein can be altered under paracetamol (APAP) treatment. APAP-protein adducts and other protein modifications (oxidation/nitration, expression) play a role in hepatotoxicity induced by acute overdoses, but it is unknown whether liver protein modifications occur during long-term treatment with non-toxic doses of APAP. We quantified APAP-protein adducts and assessed other protein modifications in the liver from rats under chronic (17d) treatment with two APAP doses (0.5% or 1% of APAP in the diet w/w). A targeted metabolomic method was validated and used to quantify APAP-protein adducts as APAP-cysteine adducts following proteolytic hydrolysis. The limit of detection was found to be 7 ng APAP-cysteine/mL hydrolysate i.e. an APAP-Cys to tyrosine ratio of 0.016 ‰. Other protein modifications were assessed on the same protein hydrolysate by untargeted metabolomics including a new strategy to process the data and identify discriminant molecules. These two complementary mass spectrometry (MS)-based metabolic approaches enabled the assessment of a wide range of protein modifications induced by chronic treatment with APAP. Copyright © 2015. Published by Elsevier B.V.
    Full-text · Article · Mar 2015 · Journal of proteomics
Show more